Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol. 1977

J A Kanis, and R G Henderson, and G Heynen, and J G Ledingham, and R G Russell, and R Smith, and R J Walton

The effects of small oral doses (1-2 microgram/day) of 1alpha-hydroxycholecalciferol, given for 1 to 2 years, have been examined in four nondialysed adolescents with chronic renal failure and bone disease. Treatment increased calcium retention and plasma calcium, and decreased plasma levels of alkaline phosphatase, hydroxyproline, and immunoreactive parathyroid hormone. X-ray abnormalities of bone regressed, and 2 patients underwent successful surgical correction of knock-knees; bone histology in these 2 was normal at the time of operation. 2 patients developed hypercalcaemia which promptly reversed when 1alpha-hydroxycholecalciferol was withdrawn. In one patient treatment was initially successful, but later there was biochemical, radiographic, and histological evidence of relapse. Long-term treatment of such patients with 1alpha-hydroxycholecalciferol may be effective and facilitate the surgical correction of deformities, but this is not invariable. Toxic effects are similar to those of vitamin D itself, but are more readily reversible.

UI MeSH Term Description Entries
D008297 Male Males
D011859 Radiography Examination of any part of the body for diagnostic purposes by means of X-RAYS or GAMMA RAYS, recording the image on a sensitized surface (such as photographic film). Radiology, Diagnostic X-Ray,Roentgenography,X-Ray, Diagnostic,Diagnostic X-Ray,Diagnostic X-Ray Radiology,X-Ray Radiology, Diagnostic,Diagnostic X Ray,Diagnostic X Ray Radiology,Diagnostic X-Rays,Radiology, Diagnostic X Ray,X Ray Radiology, Diagnostic,X Ray, Diagnostic,X-Rays, Diagnostic
D012080 Chronic Kidney Disease-Mineral and Bone Disorder Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders. Renal Osteodystrophy,Renal Rickets,Rickets, Renal,CKD-MBD,Osteodystrophy, Renal,Chronic Kidney Disease Mineral and Bone Disorder,Osteodystrophies, Renal,Renal Osteodystrophies
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006887 Hydroxycholecalciferols Hydroxy analogs of vitamin D 3; (CHOLECALCIFEROL); including CALCIFEDIOL; CALCITRIOL; and 24,25-DIHYDROXYVITAMIN D 3. Hydroxyvitamins D,Hydroxycholecalciferol
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000469 Alkaline Phosphatase An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.1.

Related Publications

J A Kanis, and R G Henderson, and G Heynen, and J G Ledingham, and R G Russell, and R Smith, and R J Walton
January 1976, Nephron,
J A Kanis, and R G Henderson, and G Heynen, and J G Ledingham, and R G Russell, and R Smith, and R J Walton
May 1977, Calcified tissue research,
J A Kanis, and R G Henderson, and G Heynen, and J G Ledingham, and R G Russell, and R Smith, and R J Walton
May 1977, Calcified tissue research,
J A Kanis, and R G Henderson, and G Heynen, and J G Ledingham, and R G Russell, and R Smith, and R J Walton
May 1976, Lancet (London, England),
J A Kanis, and R G Henderson, and G Heynen, and J G Ledingham, and R G Russell, and R Smith, and R J Walton
March 1976, Current therapeutic research, clinical and experimental,
J A Kanis, and R G Henderson, and G Heynen, and J G Ledingham, and R G Russell, and R Smith, and R J Walton
May 1977, Calcified tissue research,
J A Kanis, and R G Henderson, and G Heynen, and J G Ledingham, and R G Russell, and R Smith, and R J Walton
July 1978, Israel journal of medical sciences,
J A Kanis, and R G Henderson, and G Heynen, and J G Ledingham, and R G Russell, and R Smith, and R J Walton
January 1976, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association,
J A Kanis, and R G Henderson, and G Heynen, and J G Ledingham, and R G Russell, and R Smith, and R J Walton
January 1978, Acta medica Scandinavica,
J A Kanis, and R G Henderson, and G Heynen, and J G Ledingham, and R G Russell, and R Smith, and R J Walton
November 1970, Archives of internal medicine,
Copied contents to your clipboard!